Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | MicrobiomeTrials

← Back to trials

NCT06203600

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

RecruitingPHASE2, PHASE3INTERVENTIONAL

Trial Details

Start: 2024-06-24Est. Completion: 2027-10-31

Enrollment target: 224 participants

Locations

Baptist Health Medical Center - Little Rock, Little Rock, Arkansas, United States
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Kaiser Permanente-Anaheim, Anaheim, California, United States
Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States
Kaiser Permanente-Bellflower, Bellflower, California, United States
Tower Cancer Research Foundation, Beverly Hills, California, United States
Kaiser Permanente Dublin, Dublin, California, United States
Kaiser Permanente-Fontana, Fontana, California, United States
Kaiser Permanente-Fremont, Fremont, California, United States
Kaiser Permanente Fresno Orchard Plaza, Fresno, California, United States
Kaiser Permanente-Fresno, Fresno, California, United States
Kaiser Permanente South Bay, Harbor City, California, United States
Kaiser Permanente-Irvine, Irvine, California, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
Keck Medicine of USC Koreatown, Los Angeles, California, United States

Other microbiome trials you might be interested in

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)Phase 2Recruiting

Locally Advanced or Metastatic Malignant Solid Tumors

The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed …

Tucson, United StatesEst. completion Feb 25, 2025

Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing SurgeryPhase 2SUSPENDED

Clinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.

Nivolumab and Ipilimumab in Treating Patients With Rare TumorsPhase 2Recruiting

Acinar Cell CarcinomaAdenoid Cystic CarcinomaAdrenal Cortical CarcinomaAdrenal Gland PheochromocytomaAnal Canal Neuroendocrine CarcinomaAnal Canal Undifferentiated CarcinomaAngiosarcomaApocrine NeoplasmAppendix Mucinous AdenocarcinomaBartholin Gland Transitional Cell CarcinomaBasal Cell CarcinomaBladder AdenocarcinomaBreast Metaplastic CarcinomaCervical AdenocarcinomaCholangiocarcinomaChordomaColorectal Squamous Cell CarcinomaDesmoid FibromatosisEndometrial Transitional Cell CarcinomaEndometrioid AdenocarcinomaEsophageal Neuroendocrine CarcinomaEsophageal Undifferentiated CarcinomaExtrahepatic Bile Duct CarcinomaExtramammary Paget DiseaseFallopian Tube AdenocarcinomaFallopian Tube Transitional Cell CarcinomaFibromyxoid TumorGallbladder CarcinomaGastric Neuroendocrine CarcinomaGastric Squamous Cell CarcinomaGastric Undifferentiated CarcinomaGastrointestinal Stromal TumorGestational Trophoblastic TumorGiant Cell CarcinomaHuman Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-TypeIntestinal Neuroendocrine CarcinomaIntrahepatic CholangiocarcinomaLung Neuroendocrine TumorLung Sarcomatoid CarcinomaMajor Salivary Gland CarcinomaMalignant Neoplasm of Unknown PrimaryMalignant Odontogenic NeoplasmMalignant Peripheral Nerve Sheath TumorMalignant Solid NeoplasmMalignant Testicular Sex Cord-Stromal TumorMetastatic Pituitary Neuroendocrine TumorMinimally Invasive Lung AdenocarcinomaMixed Mesodermal (Mullerian) TumorMucinous AdenocarcinomaMucinous CystadenocarcinomaNasal Cavity AdenocarcinomaNasal Cavity CarcinomaNasopharyngeal CarcinomaNasopharyngeal Low Grade Papillary AdenocarcinomaNasopharyngeal Undifferentiated CarcinomaOral Cavity CarcinomaOropharyngeal Undifferentiated CarcinomaOvarian AdenocarcinomaOvarian Germ Cell TumorOvarian Mucinous AdenocarcinomaOvarian Squamous Cell CarcinomaOvarian Transitional Cell CarcinomaPancreatic Acinar Cell CarcinomaPancreatic Neuroendocrine CarcinomaParagangliomaParanasal Sinus AdenocarcinomaParanasal Sinus CarcinomaParathyroid Gland CarcinomaPEComaPenile Squamous Cell CarcinomaPeritoneal Mesothelial NeoplasmPlacental ChoriocarcinomaPrimary Peritoneal High Grade Serous AdenocarcinomaPseudomyxoma PeritoneiRare DisorderScrotal Squamous Cell CarcinomaSeminal Vesicle AdenocarcinomaSeminomaSerous CystadenocarcinomaSmall Intestinal AdenocarcinomaSmall Intestinal Squamous Cell CarcinomaSpindle Cell NeoplasmTeratoma With Somatic-Type MalignancyTesticular Non-Seminomatous Germ Cell TumorThyroid Gland CarcinomaTracheal CarcinomaTransitional Cell CarcinomaUreter AdenocarcinomaUreter Squamous Cell CarcinomaUrethral AdenocarcinomaUrethral Squamous Cell CarcinomaVaginal AdenocarcinomaVaginal Squamous Cell Carcinoma, Not Otherwise SpecifiedVulvar Carcinoma

This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclona…

Birmingham, United StatesEst. completion May 1, 2026